JOURNAL ARTICLE
REVIEW
Treatment of early-stage Hodgkin's disease.
Seminars in Hematology 1999 July
The management of early-stage Hodgkin's disease has been evolving over the past 25 years, largely due to recognition of early and late complications associated with radiation therapy and the demonstration of minimally toxic but effective chemotherapy. Thus, extended-field radiation is no longer the "gold standard" of treatment. Rather, combined modality approaches with abbreviated chemotherapy and limited radiation, which obviates the need for precise staging offered by laparotomy, provide excellent results with the potential for fewer adverse late effects. Several controlled clinical trials are ongoing to determine the minimal duration of chemotherapy and extent and dose of radiotherapy that will not compromise the excellent cure rate of early-stage disease.
Full text links
Trending Papers
Dilated cardiomyopathy: causes, mechanisms, and current and future treatment approaches.Lancet 2023 September 17
Management of adult-onset Still's disease: evidence- and consensus-based recommendations by experts.Rheumatology 2023 September 6
Midline incisional hernia guidelines: the European Hernia Society.British Journal of Surgery 2023 September 20
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app